Status and phase
Conditions
Treatments
About
Lenalidomide Based Immunotherapy in the Treatment of FL
Full description
Lenalidomide Based Immunotherapy efficacy related molecular biomarker in follicular lymphoma
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients diagnose as de novo or relapse refractory FL grade 1-3A .
No history of stem cell transplantation.
Written informed consent.
Exclusion criteria
Chemotherapy or large field radiotherapy within 3 weeks prior to entering the study.
Clinically significant active infection.
Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule.
Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures.
Subject has ≥grade 2 peripheral neuropathy or grade 1 with pain within 14 days before enrollment.
Patients who are pregnant or breast-feeding.
HIV infection.
Primary purpose
Allocation
Interventional model
Masking
115 participants in 1 patient group
Loading...
Central trial contact
Weili Zhao
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal